Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease
Links shared publicly online about this topic.
- 1,306total visits
Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease
Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease
View full resource at novartis.com
Tags: Vaccination, Disease and Condition, Vaccine, Novartis
Most Recently Shared on March 18, 2010 at 1:25 pm By:
Novartis gets approval in EU 4 Menveo®, 1st quadrivalent conjugate vaccine in EU to help prevent meningococcal disease - http://ow.ly/1nMHN
Also Shared By:
Advertisement
Novartis
@Novartis
EC licenses NVS Menveo vaccine to help protect people ages 11+ at risk of contracting meningococcal disease: http://bit.ly/cbKt7t
1 year ago...